ChemMedChem, Год журнала: 2024, Номер unknown
Опубликована: Июль 31, 2024
Abstract Nuclear factor erythroid 2‐related (Nrf2) is a cytoprotective transcription that induces the of genes responsible for cell's response to oxidative stress. While Nrf2 activation has led development clinically relevant therapeutics, oncogenic role in proliferation cancer cells underscored complex nature and necessity inhibitors. Although application inhibitors appears limited as anticancer agents, recent studies have begun pinpoint impairment autophagy diseases cellular marker shifts from protective deleterious state. Therefore, cytoplasmic accumulation can lead lipid hydroperoxides and, ultimately, ferroptosis. However, some aimed at elucidating non‐cancer yielded conflicting results, attributed differences approaches used inhibit or activate Nrf2, well variations vitro and/or vivo disease models. Overall, these results highlight deeper evaluation Nrf2′s diseases, especially chronic diseases. In this review, we discuss where inhibition holds potential beneficial therapeutic effects summarize recently reported exploiting medicinal chemistry suitable targeting factors like Nrf2.
Язык: Английский